FDA To Review Rules Regarding Manufacturing Infant Formula

Video Credit: Wibbitz Top Stories
Published on November 16, 2022 - Duration: 01:31s

FDA To Review Rules Regarding Manufacturing Infant Formula

FDA To Review , Rules Regarding Manufacturing , Infant Formula .

On November 15, the United States Food and Drug Administration said it would review guidance and rules regarding the manufacturing of infant formula.

On November 15, the United States Food and Drug Administration said it would review guidance and rules regarding the manufacturing of infant formula.

Fox News reports that the decision is part of the U.S. health regulator's strategy to prevent bacterial illness similar to that found in Abbot Laboratories' products this year.

Fox News reports that the decision is part of the U.S. health regulator's strategy to prevent bacterial illness similar to that found in Abbot Laboratories' products this year.

The FDA will also reportedly weigh whether to establish a dedicated group of investigators to facilitate regulatory oversight of infant formula.

The regulator is considering realigning its staff across two of its divisions to better support oversight, among other new measures.

.

The regulator is considering realigning its staff across two of its divisions to better support oversight, among other new measures.

.

The announcement comes after a major baby formula shortage earlier this year that sent parents in the U.S. scrambling.

.

The shortage was caused by a shutdown at Abbott's Michigan plant after complaints of infection by a bacteria known as cronobacter sakazakii.

The shortage was caused by a shutdown at Abbott's Michigan plant after complaints of infection by a bacteria known as cronobacter sakazakii.

Fox News reports that while the bacterial infection is considered rare, it can be deadly to newborns.

Abbott's baby formula products were recalled after reports of four cases and two deaths.

In September, the FDA said that its response to the infant formula shortage was hampered by delays and outdated technology.

In September, the FDA said that its response to the infant formula shortage was hampered by delays and outdated technology.

In a 10-page report, the FDA said that "inadequate processes and lack of clarity" related to whistleblower complaints could have slowed the agency's response.

In a 10-page report, the FDA said that "inadequate processes and lack of clarity" related to whistleblower complaints could have slowed the agency's response


You are here


๐Ÿ’ก newsR Knowledge: Other News Mentions



You might like